CBIO · Categories · Form 4
CBIO - SEC Form 4 insider transactions
Crescent Biopharma Inc. (CBIO) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.
Recent Form 4 for CBIO
- Chief Scientific Officer Pinkas Jan sold $11,778 worth of Ordinary Shares (658 units at $17.90) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 21,581 units (SEC Form 4) (withholding obligation)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- Chief Medical Officer Im Ellie Eunkyung sold $11,152 worth of Ordinary Shares (623 units at $17.90) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 21,446 units (SEC Form 4) (withholding obligation)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- Officer Lynch Ryan sold $4,296 worth of Ordinary Shares (240 units at $17.90) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 13,631 units (SEC Form 4) to cover taxes4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- Chief Financial Officer Scalzo Richard William sold $10,167 worth of Ordinary Shares (568 units at $17.90) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 19,730 units (SEC Form 4) (for withholding tax)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- President and COO Mcneill Jonathan sold $77,235 worth of Ordinary Shares (4,570 units at $16.90) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 134,588 units (SEC Form 4) to cover taxes4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- Officer Bispham Barbara Harlin sold $11,098 worth of Ordinary Shares (620 units at $17.90) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 18,710 units (SEC Form 4) (for withholding tax)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- Chief Executive Officer Brumm Joshua T sold $159,775 worth of Ordinary Shares (9,447 units at $16.91) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 271,765 units (SEC Form 4) to cover taxes4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- Officer Lynch Ryan sold $8,365 worth of Ordinary Shares (465 units at $17.99) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 13,871 units (SEC Form 4) (for withholding tax)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- Chief Scientific Officer Pinkas Jan sold $23,171 worth of Ordinary Shares (1,288 units at $17.99) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 22,239 units (SEC Form 4) to satisfy withholding obligation4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- Officer Bispham Barbara Harlin sold $21,912 worth of Ordinary Shares (1,218 units at $17.99) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 19,330 units (SEC Form 4) (for withholding tax)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- Chief Financial Officer Scalzo Richard William sold $20,005 worth of Ordinary Shares (1,112 units at $17.99) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 20,298 units (SEC Form 4) (tax liability)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- Chief Medical Officer Im Ellie Eunkyung sold $21,930 worth of Ordinary Shares (1,219 units at $17.99) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 22,069 units (SEC Form 4) (withholding obligation)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- President and COO Mcneill Jonathan sold $369,677 worth of Ordinary Shares (20,549 units at $17.99) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 139,158 units (SEC Form 4) (for tax liability)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- Chief Executive Officer Brumm Joshua T sold $761,067 worth of Ordinary Shares (42,305 units at $17.99) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 281,212 units (SEC Form 4) (tax liability)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- SEC Form 4 filed by Director Violin Jonathan4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- SEC Form 4 filed by Director Lubner David Charles4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- SEC Form 4 filed by Director Balcom Alexandra4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- SEC Form 4 filed by Director Moran Susan4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- SEC Form 4 filed by Director Fairmount Funds Management Llc4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- Chief Scientific Officer Pinkas Jan was granted 22,507 units of Ordinary Shares (SEC Form 4)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- Chief Business Officer Doughty Christopher Grant was granted 22,714 units of Ordinary Shares, increasing direct ownership by 58% to 62,194 units (SEC Form 4)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- Chief Executive Officer Brumm Joshua T was granted 55,117 units of Ordinary Shares, increasing direct ownership by 21% to 323,517 units (SEC Form 4)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- Chief Financial Officer Scalzo Richard William was granted 19,422 units of Ordinary Shares (SEC Form 4)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- President and COO Mcneill Jonathan was granted 25,507 units of Ordinary Shares, increasing direct ownership by 19% to 159,707 units (SEC Form 4)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- Chief Medical Officer Im Ellie Eunkyung was granted 21,298 units of Ordinary Shares (SEC Form 4)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- Officer Lynch Ryan was granted 12,378 units of Ordinary Shares (SEC Form 4)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- Officer Bispham Barbara Harlin was granted 18,422 units of Ordinary Shares (SEC Form 4)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- SEC Form 4 filed by President and COO Mcneill Jonathan4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- SEC Form 4 filed by Chief Executive Officer Brumm Joshua T4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- SEC Form 4 filed by Chief Scientific Officer Pinkas Jan4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- Luo Ying acquired 2,840,376 shares (SEC Form 4)4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- SEC Form 4 filed by Ye Weiguo4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- SEC Form 4 filed by Ma Songjiang4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- SEC Form 4 filed by Chen Ruoyu4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- Gni Group Ltd. acquired 63,588,119 shares (SEC Form 4)4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- SEC Form 4 filed by Wu Charles C4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- SEC Form 4 filed by Luo Ying4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- SEC Form 4 filed by Eastling Thomas Wilson4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- SEC Form 4 filed by Usman Nassim4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- SEC Form 4 filed by Ying Han4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- SEC Form 4 filed by Parry Renate4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- SEC Form 4 filed by Chen Ruoyu4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- SEC Form 4 filed by Carmichael Gordon4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- Gni Hong Kong Ltd disposed of 5,371,304 shares, closing all direct ownership in the company (SEC Form 4)4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
- SEC Form 4: Miller Seline E. returned 6 units of Series Y Preferred Stock to the company, closing all direct ownership in the company4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
- SEC Form 4: Lawlor Augustine returned 49 units of Series Y Preferred Stock to the company, closing all direct ownership in the company4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
- SEC Form 4: Usman Nassim returned 34 units of Series Y Preferred Stock to the company, closing all direct ownership in the company4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
- SEC Form 4: Gni Group Ltd. returned 6,267 units of Series Y Preferred Stock to the company4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
- SEC Form 4: Hunt Andrea returned 28 units of Series Y Preferred Stock to the company, closing all direct ownership in the company4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
- SEC Form 4: Usman Nassim bought $1,528 worth of shares (3,250 units at $0.47), increasing direct ownership by 15% to 24,541 units4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
- SEC Form 4: Miller Seline E. bought $1,528 worth of shares (3,250 units at $0.47), increasing direct ownership by 100% to 6,500 units4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
- SEC Form 4: Blouse Grant E. bought $1,528 worth of shares (3,250 units at $0.47), increasing direct ownership by 53% to 9,417 units4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
- SEC Form 4 filed by Miller Seline E.4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
- SEC Form 4 filed by Blouse Grant E.4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
- SEC Form 4: Usman Nassim bought $1,495 worth of shares (3,250 units at $0.46), increasing direct ownership by 18% to 21,291 units4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
- SEC Form 4: Miller Seline E. bought $1,495 worth of shares (3,250 units at $0.46)4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
- SEC Form 4: Blouse Grant E. bought $1,495 worth of shares (3,250 units at $0.46), increasing direct ownership by 111% to 6,167 units4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
- SEC Form 4: Williams Eddie was granted 12,308 shares, increasing direct ownership by 55% to 34,804 units4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
- SEC Form 4: Ling Geoffrey M.D. was granted 12,855 shares, increasing direct ownership by 68% to 31,790 units4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)
- SEC Form 4: Hunt Andrea was granted 7,521 shares, increasing direct ownership by 36% to 28,228 units4 - CATALYST BIOSCIENCES, INC. (0001124105) (Issuer)